$7.17
-0.04-0.55%
At close: -
$7.17
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Amneal Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AMRX | Benzinga
Amneal Pharmaceuticals Inc has a consensus price target of $9.29 based on the ratings of 7 analysts. The high is $12 issued by JP Morgan on February 24, 2025. The low is $4 issued by BMO Capital on March 3, 2023. The 3 most-recent analyst ratings were released by Barclays, JP Morgan, and Piper Sandler on March 3, 2025, February 24, 2025, and November 11, 2024, respectively. With an average price target of $11.33 between Barclays, JP Morgan, and Piper Sandler, there's an implied 58.07% upside for Amneal Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
JP Morgan
Piper Sandler
Truist Securities
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Amneal Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 53.42% | Barclays | Balaji Prasad51% | $10 → $11 | Maintains | Overweight | Get Alert |
| 02/24/2025 | Buy Now | 67.36% | JP Morgan | Chris Schott59% | $9 → $12 | Upgrade | Neutral → Overweight | Get Alert |
| 11/11/2024 | Buy Now | 53.42% | Piper Sandler | David Amsellem69% | $9 → $11 | Maintains | Overweight | Get Alert |
| 10/02/2024 | Buy Now | 67.36% | Truist Securities | Les Sulewski20% | $10 → $12 | Maintains | Buy | Get Alert |
| 09/06/2024 | Buy Now | 25.52% | JP Morgan | Chris Schott59% | → $9 | Upgrade | Underweight → Neutral | Get Alert |
| 08/13/2024 | Buy Now | 39.47% | Barclays | Balaji Prasad51% | $8 → $10 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 39.47% | Truist Securities | Les Sulewski20% | $9 → $10 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 11.58% | Goldman Sachs | Nathan Rich43% | $6.25 → $8 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 25.52% | Truist Securities | Les Sulewski20% | $7 → $9 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | Buy Now | 11.58% | Piper Sandler | David Amsellem69% | $6 → $8 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | -12.83% | Goldman Sachs | Nathan Rich43% | $5.5 → $6.25 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 11.58% | Barclays | Balaji Prasad51% | $6 → $8 | Maintains | Overweight | Get Alert |
| 11/08/2023 | Buy Now | -2.37% | Truist Securities | Gregory Fraser64% | $6 → $7 | Maintains | Buy | Get Alert |
| 09/06/2023 | Buy Now | -16.32% | Truist Securities | Gregory Fraser64% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | -30.26% | Piper Sandler | David Amsellem69% | $3 → $5 | Maintains | Overweight | Get Alert |
| 08/07/2023 | Buy Now | -16.32% | Truist Securities | Gregory Fraser64% | $4 → $6 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | -30.26% | Barclays | Balaji Prasad51% | $4 → $5 | Maintains | Overweight | Get Alert |
| 05/08/2023 | Buy Now | -58.16% | Piper Sandler | David Amsellem69% | $5 → $3 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | -44.21% | Truist Securities | Gregory Fraser64% | $5 → $4 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | -44.21% | Barclays | Balaji Prasad51% | $7 → $4 | Maintains | Overweight | Get Alert |
| 03/03/2023 | Buy Now | -58.16% | Goldman Sachs | Nathan Rich43% | $3.5 → $3 | Maintains | Buy | Get Alert |
| 03/03/2023 | Buy Now | -44.21% | BMO Capital | Gary Nachman57% | $5 → $4 | Maintains | Market Perform | Get Alert |
| 08/08/2022 | Buy Now | -44.21% | Goldman Sachs | Nathan Rich43% | $4.5 → $4 | Maintains | Buy | Get Alert |
| 05/12/2022 | Buy Now | -37.24% | Goldman Sachs | Nathan Rich43% | $6 → $4.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Amneal Pharmaceuticals (AMRX) stock?
The latest price target for Amneal Pharmaceuticals (NASDAQ:AMRX) was reported by Barclays on March 3, 2025. The analyst firm set a price target for $11.00 expecting AMRX to rise to within 12 months (a possible 53.42% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amneal Pharmaceuticals (AMRX)?
The latest analyst rating for Amneal Pharmaceuticals (NASDAQ:AMRX) was provided by Barclays, and Amneal Pharmaceuticals maintained their overweight rating.
When was the last upgrade for Amneal Pharmaceuticals (AMRX)?
The last upgrade for Amneal Pharmaceuticals Inc happened on February 24, 2025 when JP Morgan raised their price target to $12. JP Morgan previously had a neutral for Amneal Pharmaceuticals Inc.
When was the last downgrade for Amneal Pharmaceuticals (AMRX)?
There is no last downgrade for Amneal Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Amneal Pharmaceuticals (AMRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amneal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amneal Pharmaceuticals was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating Amneal Pharmaceuticals (AMRX) correct?
While ratings are subjective and will change, the latest Amneal Pharmaceuticals (AMRX) rating was a maintained with a price target of $10.00 to $11.00. The current price Amneal Pharmaceuticals (AMRX) is trading at is $7.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.